Proactive Investors - Run By Investors For Investors

Orgenesis strikes deal with Columbia University to develop Cellular Vaccination product platform

Under the deal's terms, Orgenesis will receive a license on the technology developed at Columbia
cancerous cells
Columbia has created a patented dual-vaccine - focusing on pancreatic, liver and bile duct cancers - that uses whole cancer cells as a source of antigens

Orgenesis Inc (NASDAQ:ORGS), a developer of advanced cell therapies, has struck a deal with Columbia University under which it will fund research to develop a cellular vaccination product platform.

Columbia University has created a patented dual-vaccine - focusing on pancreatic, liver and bile duct cancers - that uses whole cancer cells as a source of antigens and the patient’s own immune cells.

READ: Orgenesis strikes collaboration, license deal for exosome technologies with ExcellaBio

Under the terms of the research pact, Orgenesis will receive an exclusive license on the technology developed at Columbia.

“There are very little treatment options for pancreatic, hepatic and cholangiocarcinoma cancers and this vaccine is promising because it complements the immune response and has a broad appeal because of the ease of administration and lack of significant side effects,” said Vered Caplan, CEO of Orgenesis, in a statement.  “Moreover, this technology can serve in the future as a platform to treat many types of solid tumors.”

Columbia's patented dual-vaccine design uses whole cancer cells as a source of antigens and a patient’s dendritic cells and macrophages to present the cancer antigens to the immune system.

Targeting the full repertoire of tumor cell antigens leaves little or no possibility for cancer cells to escape the immune system’s response, according to Orgenesis.

Orgenesis is a biotechnology company specializing in the development and manufacturing of technologies in the cell and gene therapy industry.

Orgenesis shares held steady at $4.73 in Monday morning trade.

Contact Ellen Kelleher at [email protected]

 

View full ORGS profile View Profile

Orgenesis Timeline

Related Articles

test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile
antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
consumer health segment overview
January 10 2019
The company sells clinically validated anti-ageing products for hair, skin and body.
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use